NCT02734173View on ClinicalTrials.gov

Pilot HCV Direct Acting Antiviral Therapy and Metabolism

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

May 31, 2017

Conditions
Hepatitis C
Interventions
DRUG

ABT450r-ABT267-ABT333 +/- Ribavirin

12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin

Trial Locations (1)

Unknown

The Ottawa Hospital, General Campus, Ottawa

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Ottawa Hospital Research Institute

OTHER